

REMARKS

The Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, dated March 8, 2001, indicated that SEQ. ID. NOS.: 3 and 4 contained the base "n", and that an explanation of the location of "n" and which base "n" represents must be included in the Sequence Listing.


The amended Sequence Listing set forth on the substitute sheets enclosed herewith explain the location of "n" and indicates the residue is inosine ("i"). Support for the amendments to the Sequence Listing can be found in the specification as originally filed on page 14, lines 18-19, which discloses that the primers have the sequences 5'-TGGCARCCITCICARTAYGA-3' and 5'-CATRATYTTYTCICCCICCCAT-3'. Thus, "n" in the primer sequences "i". The amended Sequence Listing set forth on the substitute sheets contains no new matter.

A disk containing a computer readable form of the amended Sequence Listing is enclosed herewith. The information recorded in computer readable form is identical to the amended Sequence Listing set forth on the substitute paper copy. The attached diskette is submitted in American Standard Code for Information Interchange (ASCII) text.

A copy of the Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures is enclosed herewith.

Respectfully submitted,

MARTIN ADAMCZEWSKI
CHRISTOPH METHFESSEL
THOMAS SCHULTE


Jackie Ann Zurcher
Reg. No. 42,251
Attorney for Applicants

Bayer Corporation
Pittsburgh, PA 15205-9741
(412) 777-8359
FACSIMILE PHONE NUMBER:
412-777-8363
s:\ks\JAZ0011

Mo-6000/LeA 34,147

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Sequence Listing:

Please replace the pages titled "Sequence Listing" with the substitute amended "Sequence Listing" pages submitted herewith.